Introduction {#H1-1-ZLD200135}
============

Pulmonary edema is a prominent feature in patients with severe coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters the cell via angiotensin-converting enzyme 2 (ACE2).^[@zld200135r1]^ ACE2 is involved in degrading the kinin des-Arg^9^-bradykinin, a potent vasoactive peptide that can cause vascular leakage. Loss of ACE2 might lead to plasma leakage and further activation of the plasma kallikrein-kinin system with more bradykinin formation that could contribute to pulmonary angioedema via stimulation of bradykinin 2 receptors.^[@zld200135r2]^ We investigated whether treatment with the bradykinin 2 receptor antagonist icatibant in patients with COVID-19 could be used as a treatment strategy.

Methods {#H1-2-ZLD200135}
=======

This case-control study was approved by CMO region Arnhem-Nijmegen, the local ethical committee, which granted a waiver of consent because treatment concerned a licensed drug that would be given in an off-label setting. Informed consent was obtained in all patients. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline. Patients with COVID-19 were admitted from March to May 2020. We included 10 patients for treatment with 3 doses of 30 mg of icatibant (Firazyr; Shire Pharmaceuticals Ireland Limited) by subcutaneous injection at 6-hour intervals.^[@zld200135r3]^ Patients were eligible for icatibant treatment if they had confirmed SARS-CoV-2 by polymerase chain reaction assay, an oxygen saturation of less than 90% without supplemental oxygen, needed 3 L/min supplemental oxygen or more, and had a computed tomography severity score of 7 or greater.^[@zld200135r4]^ Patients with acute ischemic events at time of eligibility were excluded. For 9 patients who received icatibant on the ward, 2 matched control patients admitted prior to approval of this treatment were selected. Control patients with COVID-19 were matched on the factors sex, age, body mass index, and day of illness. One patient started receiving icatibant in the intensive care unit and was transferred to the ward with high-flow oxygen supplementation within 24 hours and discharged on day 7. We did not identify a matched control for this patient, so we were not able to evaluate the association of icatibant with outcomes for this individual. A change in oxygen need and oxygenation expressed as absolute number of liters per hour served as the primary outcome variable. Secondary outcomes included changes in D-dimer (dimerized plasmin fragment D), fever, and safety.

Results {#H1-3-ZLD200135}
=======

Nine cases were matched to 18 controls. The mean (SD) age was 55 (12.8) years for cases and 58 (10.5) years for controls. Most cases (9 of 10 \[90%\]) and controls (16 of 18 \[90%\]) were men. Patient and matched control characteristics are shown in the [Table](#zld200135t1){ref-type="table"}. Nine patients were prescribed icatibant on the ward. In all 9 patients, there was a marked decrease in oxygen supplementation ([Figure](#zld200135f1){ref-type="fig"}). After 3 injections of icatibant, 4 patients (44%) were no longer oxygen dependent within 10 to 35 hours. In 5 patients (56%), there was a substantial decrease of oxygen supplementation after treatment with icatibant ([Figure](#zld200135f1){ref-type="fig"}). Overall, in 8 of 9 patients (89%) treated with icatibant, a reduction of 3 L/min in oxygen supplementation or greater after 24 hours was observed ([Figure](#zld200135f1){ref-type="fig"}). Of 18 matched controls, only 3 (17%) showed a spontaneous reduction in oxygen supplementation of 3 L/min or greater within 24 hours. We noted that in 3 patients treated with icatibant there was a resurgence in the need for oxygen supplementation. Icatibant treatment was well tolerated in all 10 patients who received the drug. There were no severe adverse events. There was no clear association with D-dimer concentrations and fever.

###### Characteristics of 10 COVID-19 Patients With Icatibant Treatment and Matched Controls

  Participant No./sex/age (decade)   BMI   Days of illness[^a^](#zld200135t1n1){ref-type="table-fn"}   D-dimer, ng/mL   Temperature at admission, °C   
  ---------------------------------- ----- ----------------------------------------------------------- ---------------- ------------------------------ ------
  **Cases**                                                                                                                                            
  1/M/30s                            23    12                                                          3760             11 530                         39.9
  2/M/50s                            30    15                                                          650              \<500                          40.0
  3/M/60s                            29    10                                                          NA               690                            38.4
  4/M/40s                            27    12                                                          NA               920                            40.0
  5/M/60s                            26    11                                                          530              630                            39.3
  6/M/70s                            24    7                                                           NA               \<500                          39.1
  7/M/30s                            25    8                                                           1730             3560                           38.3
  8/M/60s                            33    10                                                          870              1240                           37.1
  9/F/50s                            32    11                                                          1590             1030                           40.1
  10/M/40s                           28    15                                                          1600             1000                           37.1
  **Controls**                                                                                                                                         
  1a/M/30s                           23    2                                                           1360             NA                             38.1
  1b/M/40s                           27    13                                                          1750             NA                             37.8
  2a/M/50s                           26    15                                                          1360             780                            36.9
  2b/M/50s                           27    15                                                          1500             NA                             39.9
  3a/M/60s                           25    9                                                           NA               NA                             37.1
  3b/M/70s                           25    9                                                           3710             3710                           39.2
  4a/M/50s                           28    10                                                          760              700                            39.4
  4b/M/50s                           27    8                                                           620              500                            39.6
  5a/M/60s                           22    11                                                          1520             940                            37.1
  5b/M/60s                           27    11                                                          1550             1340                           39.4
  6a/M/60s                           25    6                                                           700              840                            38.2
  6b/M/70s                           29    8                                                           3660             2080                           37.7
  7a/M/40s                           21    5                                                           33 790           7060                           36.9
  7b/M/40s                           31    12                                                          2210             1660                           38.0
  8a/F/60s                           36    4                                                           1740             NA                             38.7
  8b/F/60s                           27    11                                                          510              600                            38.0
  9a/M/50s                           22    10                                                          \<500            \<500                          39.5
  9b/M/50s                           22    14                                                          3300             2150                           38.8

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); COVID-19, coronavirus disease 2019; D-dimer, dimerized plasmin fragment D; F, female; M, male; NA, not applicable.

SI conversion: To convert D-dimer to nmol/L, multiply by 5.476.

Days of illness at start icatibant or 24 hours after admission (controls).

D-dimer 24 hours after icatibant or 48 hours after admission (controls).

![Changes in Oxygen Supplementation at Baseline and 24 Hours in Individual Patients and Controls\
Oxygen supplementation in individual patients (n = 9) and matched controls (n = 18).](jamanetwopen-3-e2017708-g001){#zld200135f1}

Discussion {#H1-4-ZLD200135}
==========

This study found evidence of an association between receipt of icatibant and improved oxygenation, suggesting that targeting the kallikrein-kinin system in patients with COVID-19, especially in the early stages of disease when patients are hypoxic and are admitted to the hospital, might be beneficial. An important limitation of the current study is that it is exploratory and not a randomized clinical trial. The observed resurgence of oxygen need in some patients after icatibant may be due to icatibant's short half life of about 2 hours.^[@zld200135r3]^ We propose that treatment strategies targeting the kallikrein-kinin system should be investigated in randomized trials for patients with COVID-19.
